Pharmaceutical industry bosses are reviewing the level of transparency related to coronavirus trials amid concerns over the pausing of the Oxford University and Astrazeneca studies.
Pascal Soriot, the chief executive of the Cambridge-based FTSE 100 company Astrazeneca, said today that it was discussing with other companies “what kind of transparency we could offer without compromising patient privacy [and] the trial itself”.
“We are trying to come up with a consensus that is what we feel is reasonable to disclose, that is typically not disclosed, but in this special set of circumstances where of course people want maximum transparency.”
He said clinical guidelines recommended that drug companies “don’t disclose patient-level information and also that you don’t disclose much information at all because you could compromise the